These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 2191470

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Genetic polymorphism of the hepatic metabolism of drugs].
    Larrey D, Pessayre D, Benhamou JP.
    Gastroenterol Clin Biol; 1985; 9(6-7):522-31. PubMed ID: 3926587
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [In vitro tests of hepatic oxidation in man, predictive of drug interactions].
    Dayer P, Leemann T, Striberni R, Meyer P.
    Schweiz Med Wochenschr; 1987 Dec 05; 117(49):1971-3. PubMed ID: 3423780
    [Abstract] [Full Text] [Related]

  • 6. The influence of circadian rhythms on the kinetics of drugs in humans.
    Baraldo M.
    Expert Opin Drug Metab Toxicol; 2008 Feb 05; 4(2):175-92. PubMed ID: 18248311
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Individual variations in the oxidative metabolism of drugs. Significance of monogenic polymorphism].
    Brøsen K.
    Ugeskr Laeger; 1984 Mar 26; 146(13):955-9. PubMed ID: 6719598
    [No Abstract] [Full Text] [Related]

  • 11. First-principle, structure-based prediction of hepatic metabolic clearance values in human.
    Li H, Sun J, Sui X, Liu J, Yan Z, Liu X, Sun Y, He Z.
    Eur J Med Chem; 2009 Apr 26; 44(4):1600-6. PubMed ID: 18768239
    [Abstract] [Full Text] [Related]

  • 12. Effect of Fluosol-DA hemodilution on the kinetics of hepatically eliminated drugs.
    Shrewsbury RP.
    Res Commun Chem Pathol Pharmacol; 1987 Mar 26; 55(3):375-96. PubMed ID: 3575876
    [Abstract] [Full Text] [Related]

  • 13. Prediction of human pharmacokinetics--improving microsome-based predictions of hepatic metabolic clearance.
    Fagerholm U.
    J Pharm Pharmacol; 2007 Oct 26; 59(10):1427-31. PubMed ID: 17910819
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
    Faber MS, Jetter A, Fuhr U.
    Basic Clin Pharmacol Toxicol; 2005 Sep 26; 97(3):125-34. PubMed ID: 16128905
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C, Nalda Molina R, González-Alvarez I, Navarro-Fontestad C, García-Arieta A, Casabó VG, Bermejo M.
    Eur J Pharm Sci; 2009 Jan 31; 36(1):137-46. PubMed ID: 19028574
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.